Hormonal contraception and lymphoma risk in danish women 15-49 years: a nationwide cohort study.
코호트
1/5 보강
[BACKGROUND] Lymphomas occur less frequently in women than men, but the causes remain unclear.
- 95% CI 0.75-0.94
APA
Hemmingsen CH, Mørch LS, et al. (2025). Hormonal contraception and lymphoma risk in danish women 15-49 years: a nationwide cohort study.. Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaf371
MLA
Hemmingsen CH, et al.. "Hormonal contraception and lymphoma risk in danish women 15-49 years: a nationwide cohort study.." Journal of the National Cancer Institute, 2025.
PMID
41429564
Abstract
[BACKGROUND] Lymphomas occur less frequently in women than men, but the causes remain unclear. Given the immunomodulatory potential of female hormones, hormonal contraceptive use could influence lymphoma risk, yet existing research is inconclusive.
[METHODS] We investigated the relationship between contemporary hormonal contraceptive use and lymphoma risk in a nationwide Danish cohort of women aged 15-49 years (1995-2021). Women with prior cancer, hysterectomy, oophorectomy, or sterilization were excluded. Data on hormonal contraceptive use, lymphomas, and confounders were retrieved from national registries. Incidence rate ratios (IRRs) with 95% confidence intervals (CIs) were estimated for any hormonal contraceptive use and lymphoma risk, including lymphoma subtypes, contraceptive types, duration of use, and time since last use. All statistical tests were two-sided.
[RESULTS] During 24.5 million person-years of follow-up, 1777 lymphomas (686 Hodgkin, 1091 non-Hodgkin) occurred among 1,957,490 women. Ever using hormonal contraception was associated with reduced lymphoma risk (IRR 0.84, 95%CI 0.75-0.94), with similar IRRs across lymphoma types. This was driven by current/recent use of both combined products (IRR 0.80, 95%CI 0.70-0.91) and progestin-only products (IRR 0.81, 95%CI 0.67-0.97), especially oral combined and non-oral progestin-only products. Risk decreased with longer use, with the lowest risk for use >10 years (IRR 0.53, 95%CI 0.33-0.85), but no long-term sustained protective effect was seen after cessation.
[CONCLUSION] The findings indicate that hormonal contraceptive use may have a role in lymphoma etiology and confer protective effects, underscoring the need to explore hormonal pathways in both a preventive and therapeutic context.
[METHODS] We investigated the relationship between contemporary hormonal contraceptive use and lymphoma risk in a nationwide Danish cohort of women aged 15-49 years (1995-2021). Women with prior cancer, hysterectomy, oophorectomy, or sterilization were excluded. Data on hormonal contraceptive use, lymphomas, and confounders were retrieved from national registries. Incidence rate ratios (IRRs) with 95% confidence intervals (CIs) were estimated for any hormonal contraceptive use and lymphoma risk, including lymphoma subtypes, contraceptive types, duration of use, and time since last use. All statistical tests were two-sided.
[RESULTS] During 24.5 million person-years of follow-up, 1777 lymphomas (686 Hodgkin, 1091 non-Hodgkin) occurred among 1,957,490 women. Ever using hormonal contraception was associated with reduced lymphoma risk (IRR 0.84, 95%CI 0.75-0.94), with similar IRRs across lymphoma types. This was driven by current/recent use of both combined products (IRR 0.80, 95%CI 0.70-0.91) and progestin-only products (IRR 0.81, 95%CI 0.67-0.97), especially oral combined and non-oral progestin-only products. Risk decreased with longer use, with the lowest risk for use >10 years (IRR 0.53, 95%CI 0.33-0.85), but no long-term sustained protective effect was seen after cessation.
[CONCLUSION] The findings indicate that hormonal contraceptive use may have a role in lymphoma etiology and confer protective effects, underscoring the need to explore hormonal pathways in both a preventive and therapeutic context.